


## Telratolimod

<b>Cat. No.:</b>	HY-109104												
<b>CAS No.:</b>	1359993-59-1												
<b>Molecular Formula:</b>	C <sub>36</sub> H <sub>59</sub> N <sub>5</sub> O <sub>2</sub>												
<b>Molecular Weight:</b>	593.89												
<b>Target:</b>	Toll-like Receptor (TLR)												
<b>Pathway:</b>	Immunology/Inflammation												
<b>Storage:</b>	<table border="0"> <tr> <td>Powder</td> <td>-20°C</td> <td>3 years</td> </tr> <tr> <td></td> <td>4°C</td> <td>2 years</td> </tr> <tr> <td>In solvent</td> <td>-80°C</td> <td>6 months</td> </tr> <tr> <td></td> <td>-20°C</td> <td>1 month</td> </tr> </table>	Powder	-20°C	3 years		4°C	2 years	In solvent	-80°C	6 months		-20°C	1 month
Powder	-20°C	3 years											
	4°C	2 years											
In solvent	-80°C	6 months											
	-20°C	1 month											



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 62.5 mg/mL (105.24 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
			10 mg	
<b>Preparing Stock Solutions</b>	<b>1 mM</b>	1.6838 mL	8.4191 mL	16.8381 mL
	<b>5 mM</b>	0.3368 mL	1.6838 mL	3.3676 mL
	<b>10 mM</b>	0.1684 mL	0.8419 mL	1.6838 mL
Please refer to the solubility information to select the appropriate solvent.				
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: 2.08 mg/mL (3.50 mM); Suspended solution; Need ultrasonic</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: 2.08 mg/mL (3.50 mM); Suspended solution; Need ultrasonic</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.08 mg/mL (3.50 mM); Clear solution</li> </ol>			

### BIOLOGICAL ACTIVITY

<b>Description</b>	Telratolimod (MEDI9197) is a potent toll like receptors 7/8 (TLR7/8) agonist, with antitumor activity <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	TLR7/8 <sup>[1]</sup>
<b>In Vitro</b>	Telratolimod (3M-052) is a toll like receptors 7/8 (TLR7/8) agonist, with antitumor activity <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

Telratolimod (50 µg) inhibits the tumor volume, and more potently blocks tumor growth in combination with CpG ODN in BALB/c mice bearing CT26 colon carcinoma cells. Telratolimod (100 µg) plus 200 µg of CpG ODN slows tumor growth and prolongs survival of mice bearing large tumors<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### CUSTOMER VALIDATION

- Patent. US 20200316211A1.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

#### REFERENCES

[1]. Zhao BG, et al. Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors. J Immunother Cancer. 2014 May 13;2:12.

**Caution: Product has not been fully validated for medical applications. For research use only.**

India Contact:

Life Technologies (India) Pvt. Ltd.

306, Aggarwal City Mall, Opposite M2K Pitampura, Delhi – 110034 (INDIA). Ph: +91-11-42208000, 42208111, 42208222, Mobile: +91-9810521400, Fax: +91-11-42208444

Email: [customerservice@lifetechindia.com](mailto:customerservice@lifetechindia.com) Website: [www.lifetechindia.com](http://www.lifetechindia.com)